2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2434 Baseline gut microbiome composition and species-level depletion of butyrate- and tryptophan-metabolizing commensals are associated with clinically significant infections following CD19 CAR T-cell therapy

Ravi Kumar Gupta, MD, Faezeh Darbaniyan, PhD2, Farzaneh Maadani3, Amy A. Ayers4, Nancy Vuong, PharmD5, Guy Handley, MD6, Adam G Stewart, MD, PhD7, Paolo Strati, MD8, Jeremy Ramdial, MD9, Samuel Shelburne, MD, PhD10, Neeraj Saini, MD11, Sairah Ahmed, MD12, Teny M John, MD, FACP13
1 UT MD Anderson Cancer Center, Houston, Texas, United States
2 UT MD Anderson Cancer Center, Houston, Texas, United States
3 UT MD Anderson Cancer Center, Houston, Texas, United States
4 UT MD Anderson Cancer Center, Houston, Texas, United States
5 UT MD Anderson Cancer Center, Houston, Texas, United States
6 UT MD Anderson Cancer Center, Houston, Texas, United States
7 UT MD Anderson Cancer Center, Houston, Texas, United States
8 UT MD Anderson Cancer Center, Houston, Texas, United States
9 UT MD Anderson Cancer Center, Houston, Texas, United States
10 UT MD Anderson Cancer Center, Houston, Texas, United States
11 UT MD Anderson Cancer Center, Houston, Texas, United States
12 UT MD Anderson Cancer Center, Houston, Texas, United States
13 UT MD Anderson Cancer Center, Houston, Texas, United States

Introduction

Infectious complications are a leading cause of non-relapse morbidity and mortality following chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Baseline gut microbiome features predict infection risk in allogeneic HCT and AML induction chemotherapy. Whether analogous associations exist in the CAR T-cell setting, which has a distinct infection biology, has not been systematically characterized. We hypothesized that baseline gut microbiome features would be associated with clinically significant infection in the first 100 days following CAR T-cell infusion.

Methods

We conducted a retrospective single-center cohort study at MD Anderson Cancer Center of adult recipients of CD19 CAR T-cell therapy for lymphoma from November 2018 to April 2022, who had banked stool samples collected within 7 days pre-infusion. Whole-genome shotgun metagenomic sequencing was performed, with species-level taxonomic profiling by MetaPhlAn4. Infection events were adjudicated by an infectious diseases physician and an oncologist using the BMT-CTN 2023 Infection Grading System. The primary endpoint was any BMT-CTN Grade ≥2 infection within 100 days of infusion. Alpha diversity (Shannon, Inverse Simpson) was compared by Welch t-test; beta diversity was assessed by PERMANOVA on Bray-Curtis dissimilarity; and differential species abundance was tested with MaAsLin2 (FDR-adjusted).

Results
Sixty-eight patients (66% DLBCL, 69% male, median age 63) contributed 102 baseline stool samples. Within 100 days, 31 patients (46%) developed at least one infection (41 events). Twenty-six patients (38%) developed Grade ≥2 infection, and 12 patients (18%) required ICU-level care. Infection sites included lungs (n=10), urinary tract (n=10), bloodstream (n=7), gastrointestinal (n=2), and other sites (n=12).

Overall microbiome composition was significantly associated with Grade ≥2 infection (PERMANOVA p=0.011, R²=0.023) and ICU-level infection (p=0.011, R²=0.023), with a weaker association for any infection (p=0.039, R²=0.018). Alpha diversity was lower in patients who developed Grade ≥2 infection (Inverse Simpson p=0.025) or required ICU care (Inverse Simpson p=0.028), with Shannon diversity showing a trend in the same direction (Grade ≥2 infection p=0.069).

Species-level analysis identified a biologically consistent baseline signature in patients who later developed Grade ≥2 infection. These patients had lower baseline abundance of multiple commensal bacteria involved in SCFA production and tryptophan metabolism, including Faecalibacterium prausnitzii, Eubacterium rectale, Coprococcus comes, Gordonibacter urolithinfaciens, Fusicatenibacter saccharivorans, and Anaerostipes hadrus. Campylobacter gracilis, Lacticaseibacillus rhamnosus, and Candidatus Nanosynsacchari were enriched in these patients.

Prior broad-spectrum antibiotic exposure (piperacillin-tazobactam, carbapenem, or cefepime) was associated with subsequent Grade ≥2 infection, with the strongest effect for the anti-anaerobic PIM class (piperacillin-tazobactam or carbapenem; OR 11.98, FDR 0.002). Prior antibiotic exposure was correlated with baseline butyrate-producer depletion (rho -0.31, p=0.002). Baseline butyrate producer abundance predicted Grade ≥2 infection (OR 0.82 per log₁₀, 95% CI 0.70-0.96, p=0.014; cross-validated AUC 0.76 versus 0.69 for age and product alone). In mediation analysis, butyrate depletion did not mediate the antibiotic effect (average causal mediation effect 12%, p=0.20), while the direct antibiotic effect on infection remained significant (p=0.002). In age- and antibiotic-adjusted models, Blautia producta was depleted with PIM (q=0.065) and Neobittarella massiliensis with cefepime (q=0.034).

Conclusions
In this discovery cohort, baseline gut microbiome features were associated with clinically significant infection within 100 days, with a signature of lower alpha diversity and depletion of butyrate- and tryptophan-metabolizing commensals. Prior broad-spectrum antibiotic exposure was strongly associated with both this baseline microbiome injury and subsequent infection, suggesting antibiotic exposure and microbiome depletion as overlapping risk factors. Baseline microbial metabolic function may be a candidate biomarker for post-CAR-T infection risk. These findings support antibiotic stewardship as a microbiome-preserving intervention and identify butyrate and tryptophan metabolic pathways as candidate targets for future microbiome-directed strategies. 

Ravi Kumar Gupta, MD: No relevant conflicts of interest to declare.